Key facts
- Deciduous Therapeutics’s last known valuation is $45.0M (May 2023).
- It has raised $26.5M across 1 recorded rounds; the latest was Early Stage VC ($5.8M) in Jun 2019.
- Notable investors include Mana Ventures, Gaingels, 8VC, CRV, Johnson & Johnson Innovation - JLABS — 20 tracked in total.
- Deciduous Therapeutics has filed 1 Form D with the SEC, most recently Jul 2019 ($5.8M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Deciduous Therapeutics
Funding rounds
1 roundsAbout Deciduous Therapeutics
Developer of novel therapeutics designed for the treatment of age-related diseases. The company's novel molecules can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells, enabling healthcare providers to treat several classes of age-related diseases.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Employees
- 13
- Website
- deciduoustx.com/
- Ownership
- Privately Held (backing)
Deciduous Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Deciduous Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Deciduous Therapeutics in its N-PORT filings yet. We sweep new filings monthly.